C
Christophe Marchand
Researcher at National Institutes of Health
Publications - 138
Citations - 8149
Christophe Marchand is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Integrase & Integrase inhibitor. The author has an hindex of 44, co-authored 137 publications receiving 7524 citations. Previous affiliations of Christophe Marchand include St. Jude Children's Research Hospital & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.
TL;DR: This review focuses on the molecular and biochemical characteristics of topoisomerases and their inhibitors and discusses the common mechanism of action ofTopoisomerase poisons by interfacial inhibition and trapping of topisomerase cleavage complexes.
Journal ArticleDOI
Integrase inhibitors to treat HIV/AIDS.
TL;DR: The main classes of lead compounds are also described, as well as the concept of interfacial inhibitors of protein-nucleic acid interactions that might apply to the clinically used strand-transfer inhibitors.
Book ChapterDOI
Repair of topoisomerase I-mediated DNA damage.
Yves Pommier,Juana M. Barcelo,Juana M. Barcelo,V. Ashutosh Rao,V. Ashutosh Rao,Olivier Sordet,Olivier Sordet,Andrew Jobson,Andrew Jobson,Laurent Thibaut,Laurent Thibaut,Ze-Hong Miao,Ze-Hong Miao,Jennifer A. Seiler,Jennifer A. Seiler,Hongliang Zhang,Hongliang Zhang,Christophe Marchand,Christophe Marchand,Keli Agama,Keli Agama,John L. Nitiss,John L. Nitiss,Christophe E. Redon,Christophe E. Redon +24 more
TL;DR: This chapter reviews the developments in several pathways involved in the repair of Top1 cleavage complexes and the role of Chk1 and Chk2 checkpoint kinases in the cellular responses to Top1 inhibitors.
Journal ArticleDOI
Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2).
TL;DR: The rationale for developing TDP inhibitors for combinations with topoisomerase inhibitors, as well as the relevance of TDP1 and TDP2 as determinants of response to anticancer agents, are discussed.
Journal ArticleDOI
Interfacial inhibitors: targeting macromolecular complexes
Yves Pommier,Christophe Marchand +1 more
TL;DR: Five archetypical examples of interfacial inhibitors are reviewed: the camptothecins, etoposide, the quinolone antibiotics, the vinca alkaloids and the novel anti-HIV inhibitor raltegravir.